Loading
PACS Group, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Dilsaver Evelyn S, was filed 26 Nov 2025.
PACS Group, Inc.: what insiders have been doing
Every trade that managers of PACS Group, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 21 October 2026, 114 filings were filed, from 16 insiders.
Both sides are active: 1 purchase worth €434k and 59 sales worth €61.2M, from 1 insider and 6 insiders respectively. On balance, insiders were net sellers of €60.8M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Hancock Mark filed the largest sale, €5.6M, on 6 July 2026, which represents 0.098% of the company's market value. Among those who bought: 1 senior executive.
With 114 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Looking back to 2024, when coverage begins, insiders filed 2 purchases and 64 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 5.29 bn USD and net income of 191.5 m USD.
The last purchase on record was published on 26 November 2025, which is 329 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
134
Thresholds
n/a
Buy Volume
€443,808
2 ops. · all time
Sell Volume
€656M
64 ops. · all time
Who traded when
BuySaleMurray Jason Hulse36 sales
Hancock Mark15 sales
Joshua Jergensen9 sales
Lewis Michelle Renee4 sales
Conway Patrick Hugh1 sale
Dilsaver Evelyn S1 buy
+1 other insider
Since the insiders bought
- +17.7%Entry US$33.41 · Close at T+90 US$39.31
- -59.4%Entry US$26.91 · Close at T+365 US$10.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate PACS Group, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$59.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,252 of 26,279 companies
38.6
score / 100
Value36
Quality41
FCF yld2.1%
Earn yld2.5%
EV/EBITDA29.9x
ROE28%
Gross mgn15%
Net mgn3.6%
Debt/EBITDA9.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$47.75
Analyst consensus
6 analystsStrong buy
US$57.00Target US$59.00(+24%)US$62.00
Income statement
RevenueUS$5.3B
Gross profitUS$780.3M15% margin
EBITDAUS$368.5M7% margin
Net incomeUS$191.5M4.8% margin
Valuation
PER (trailing)27.9x
PER (forward)17.4x
P/Book6.8x
Beta-0.08
Balance sheet & cash
Market capUS$7.6B
Total debtUS$3.5B
Free Cash FlowUS$155.1M
Debt / Equity305%
Profitability & ownership
ROE27.9%
ROA4.6%
% insiders69.0%
% institutions31.7%
Last declaration on 16 October 2026
Declarations134 total
386,667 shares@ US$47.89CommonSEC144:0001969223-26-001078
40,000 shares@ US$44.50010.024% mcap6.5% of flowCommon StockSEC:0002014275-26-000016:0
232 shares@ US$45.000.0001% mcap0.0% of flowCommon StockSEC:0002014386-26-000020:0
4,633 shares@ US$45.61170.0028% mcap0.1% of flowCommon StockSEC:0002014386-26-000020:1
24,800 shares@ US$46.78370.015% mcap0.3% of flowCommon StockSEC:0002014386-26-000020:2
77,540 shares@ US$47.49160.049% mcap0.9% of flowCommon StockSEC:0002014386-26-000020:3
3,062 shares@ US$48.10520.0019% mcap0.0% of flowCommon StockSEC:0002014386-26-000020:4
8,462 shares@ US$47.610.0053% mcap0.1% of flowCommon StockSEC:0002014386-26-000020:5
132,519 shares@ US$37.76490.071% mcap19.6% of flowCOMMONSEC144:0001949846-26-000610
28,753 shares@ US$42.95540.018% mcap0.3% of flowCommon StockSEC:0002014386-26-000018:0
7,222 shares@ US$43.6370.0047% mcap0.1% of flowCommon StockSEC:0002014386-26-000018:1
717 shares@ US$42.480.0005% mcap0.0% of flowCommon StockSEC:0002014386-26-000018:2
33,032 shares@ US$41.12550.020% mcap0.3% of flowCommon StockSEC:0002014386-26-000016:0
2,596 shares@ US$41.79020.0016% mcap0.0% of flowCommon StockSEC:0002014386-26-000016:1
23,456 shares@ US$42.59310.015% mcap0.3% of flowCommon StockSEC:0002014386-26-000016:2
24,224 shares@ US$42.65510.015% mcap0.3% of flowCommon StockSEC:0002014386-26-000016:3
3,498 shares@ US$43.61810.0023% mcap0.7% of flowCommon StockSEC:0002014275-26-000014:1
36,502 shares@ US$43.08140.024% mcap7.5% of flowCommon StockSEC:0002014275-26-000014:0
144,318 shares@ US$44.57420.097% mcap1.6% of flowCommonSEC144:0002014361-26-000033
155,682 shares@ US$42.47140.100% mcap1.7% of flowCommonSEC144:0002014361-26-000036
21,084 shares@ US$43.74850.014% mcap0.2% of flowCommon StockSEC:0002014361-26-000035:4
137,684 shares@ US$44.55820.092% mcap1.5% of flowCommon StockSEC:0002014361-26-000035:0
6,634 shares@ US$44.90520.0045% mcap0.1% of flowCommon StockSEC:0002014361-26-000035:1
104,132 shares@ US$42.09070.066% mcap1.1% of flowCommon StockSEC:0002014361-26-000035:2
30,466 shares@ US$42.88870.020% mcap0.3% of flowCommon StockSEC:0002014361-26-000035:3
25 of 134 declarations
About PACS Group, Inc.
PACS Group, Inc. is a U.S.-listed healthcare company traded on the New York Stock Exchange (NYSE) under the ticker PACS, and it is based in the United States. For French-speaking investors, the company should be viewed as a post-acute care and senior housing platform rather than a pure real estate or generic healthcare name. Founded in 2013, PACS began with just two skilled nursing facilities and has since scaled into one of the largest post-acute operators in the United States, with more than 300 affiliated facilities across 17 states. Its corporate headquarters is in Salt Lake City, Utah.
The company’s business model combines facility operations with centralized support services. PACS is primarily focused on skilled nursing facilities, while also participating in senior living, including assisted living and independent living, as well as rehabilitation and memory care services. Through its support platform, PACS Services, the company provides administrative and operational functions such as accounting, finance, human resources, payroll, information technology, compliance, legal, risk management, and corporate communications. This structure is designed to let local facility leadership focus on care delivery while benefiting from centralized scale, systems, and compliance oversight.
Read moreShow less
From a competitive standpoint, PACS emphasizes its geographic density, scale, and ability to integrate facilities efficiently. Management describes the company as one of the largest skilled nursing providers in the United States by number of facilities. That scale matters in a highly regulated, labor-intensive industry because it can improve referral relationships with hospitals and health systems, support operating leverage, and enhance the company’s ability to absorb and improve underperforming assets. The platform’s expanded footprint also gives it a broader base for occupancy recovery, clinical mix improvement, and operational optimization.
Recent developments have been constructive. PACS reported first-quarter 2026 results showing solid revenue growth and stronger profitability, and it raised its 2026 Adjusted EBITDA outlook. The company also continued to execute on acquisitions and portfolio expansion, ending the first quarter of 2026 with 324 healthcare operations across 17 states. In May 2026, the board also approved a $250 million share repurchase authorization, underscoring management’s confidence in the business and capital structure.
For investors, PACS offers exposure to U.S. demographic tailwinds tied to an aging population, but it also carries the typical risks of post-acute care: reimbursement pressure, regulatory scrutiny, staffing costs, and execution risk in integration. Overall, it is a scaled, growth-oriented post-acute care platform with a strong operating focus and a clearly defined expansion strategy.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
